Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: TARA) | Delayed: 2.41 -0.07 (2.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.48 | 52 Week High | $ | |||
| Open | $2.50 | 52 Week Low | $ | |||
| Day High | $2.52 | P/E | N/A | |||
| Day Low | $2.38 | EPS | $ | |||
| Volume | 588,552 | |||||
